Sanmai is developing a non-invasive focused ultrasound neuromodulation platform for psychiatric and neurological indications. The company is structured as a public benefit corporation and is focused on low-intensity transcranial focused ultrasound as a clinical neurotherapeutic modality. Its initial clinical work centers on anxiety disorders, with broader relevance to brain-circuit modulation in mental health.

Its lead device, Lotus, uses tFUS to modulate targeted neural circuits through acoustic stimulation. Public materials describe AI-assisted targeting software designed to personalize acoustic planning and account for skull-related beam distortion during treatment delivery. The system is framed as a clinician-facing platform for non-invasive brain stimulation.

Sanmai remains in the investigational stage, with clinical testing described around anxiety-related outcomes, electrophysiology, behavior, and cognitive markers. The company is best understood as an early clinical-stage neuromodulation developer applying focused ultrasound to psychiatric care, with acoustic targeting as the main technical differentiator.